<p><span>The COVID-19 pandemic has put a strain on the global healthcare system. In the wake of its massive negative impacts, it has positively catalyzed the development of new drugs and vaccines. The potential usage for mRNA-based pharmaceuticals, for instance, far exceeds its current application as an effective vaccine against SARS-COVID-19. Research predicts the global mRNA Vaccines and Therapeutics market to grow at a CAGR of around 13% during 2021-2026. Today, Horizons ETFs Management (Canada) Inc. (“Horizons ETFs”) has launched <a href="http://www.horizonsetfs.com/etf/HVAX">the Horizons Global Vaccines and Infectious Diseases Index ETF (“HVAX”)</a>, an ETF that provides global exposure to companies involved in vaccine development, diagnostics, and therapeutics. On the same day, the Canadian ETF provider also launched the <a href="http://www.horizonsetfs.com/etf/bldr">Horizons North American Infrastructure Development Index ETF (“BLDR”)</a>, which builds on the surge in demand of North American infrastructure companies as the current US administration proposes a bill for an extensive trillion-dollar infrastructure program.</span></p>